Mass Torts

July 21, 2026

Gambling Addiction Lawsuits

Our lawyers are investigating gambling addiction lawsuits involving DraftKings, FanDuel, BetMGM, Caesars, ESPN Bet, Bet365, Fanatics Sportsbook, Hard Rock Bet, and other online betting platforms. The central allegation is that these companies had the data to recognize compulsive gambling behavior and, instead of slowing vulnerable users down, continued pushing bonus bets, deposit matches, notifications, VIP offers, profit boosts, parlays, microbets, and personalized promotions.

If you or your child suffered serious harm from online sports betting addiction, the first question is not whether gambling was legal. The first question is whether the platform used design, data, and marketing to keep a vulnerable user betting when a responsible operator should have stepped in.

If you or someone you love has suffered severe financial and emotional harm because of addiction to online gambling or sports betting, contact our lawyers at 800-553-8082 or get a free, no-obligation online consultation.

July 15, 2026

Camp Lejeune Lawsuit News and Updates

by Ronald V. Miller, Jr.

This page provides updates on Camp Lejeune lawsuits. Our lawyers are still working to give the latest update on the litigation, even though we are no longer taking new cases. Why? Because there is little information out there, and we are staying with victims, including those we do not represent, until the end.

We have also recently reopened the comments below to answer any questions you may have or simply give you a chance to share your thoughts.

Latest Camp Lejeune Lawsuit Updates for 2026

July 14, 2026

Tylenol Autism Lawsuit

by Ronald V. Miller, Jr.

Tylenol autism lawsuits are being filed nationwide with a new Tylenol Autism class action lawsuit – technically an MDL, as we explain below – now certified in federal court.

Another Path For Victims – Baby Food

There may be another path to compensation for some victims. Plaintiffs’ Tylenol lawyers are exploring options in state court (and looking at potential baby food lawsuits for children with autism.. Those lawsuits are gaining new currency after the Tylenol cases faltered in the MDL.

July 9, 2026

Vaginal Mesh Lawsuit

by Ronald V. Miller, Jr.

Women are still filing vaginal mesh lawsuits and bladder sling lawsuits in 2026, but this is no longer the enormous federal mass tort it was a decade ago. The old federal MDLs have closed. Most legacy claims have been resolved, and the remaining litigation is concentrated in individual cases and state-court dockets, including active Johnson & Johnson and Ethicon pelvic mesh cases in New Jersey.

A viable case now depends less on the history of the old litigation and more on specific proof: the manufacturer and product, the date of implantation, mesh erosion or another documented complication, revision surgery, and medical evidence connecting the implant to the injury. Our lawyers are currently focused on selected claims involving Johnson & Johnson/Ethicon and Coloplast products. We are not accepting new Boston Scientific mesh claims.

This page provides our latest transvaginal mesh lawsuit update, explains bladder sling complications lawsuits, discusses settlement value, and answers whether it may still be possible to file. Call 800-553-8082 or contact us online for a free case review.

July 9, 2026

Monsanto Roundup Lawsuit Update

by Ronald V. Miller, Jr.

In this post, our Roundup lawyers will give you:

An update on where things stand in the new $7.5 billion Roundup class action lawsuit settlement in June 2026
The likely direction the Roundup litigation will take moving forward, and

July 6, 2026

Dupixent Lawsuit for T-Cell Lymphoma

by Ronald V. Miller, Jr.

Dupixent lawsuits are now moving forward in federal court for patients who allege the drug caused, accelerated, or unmasked cutaneous T-cell lymphoma and related T-cell lymphomas. On June 4, 2026, the Judicial Panel on Multidistrict Litigation centralized the federal Dupixent cases in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.

Dupixent, also known as dupilumab, is a biologic medication used to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, bullous pemphigoid, allergic fungal rhinosinusitis, and other inflammatory conditions. For many patients, Dupixent has provided real relief where other treatments failed. But for some patients, the story has been very different.

The lawsuits allege that Regeneron and Sanofi failed to warn doctors and patients that cutaneous T-cell lymphoma, often called CTCL, can mimic eczema and that Dupixent may mask, accelerate, or delay diagnosis of an underlying lymphoma. Plaintiffs argue that patients with adult-onset, atypical, or treatment-resistant dermatitis should have been warned to rule out lymphoma before starting Dupixent and to stop and investigate if symptoms worsened or changed during treatment.

July 3, 2026

Glucose Monitor Lawsuits

by Ronald V. Miller, Jr.

Glucose monitor lawsuits are being filed by people who say continuous glucose monitoring systems failed when they needed them most. These lawsuits involve Dexcom G6, Dexcom G7, Abbott FreeStyle Libre 3, and Abbott FreeStyle Libre 3 Plus sensors, apps, and receivers that allegedly provided inaccurate glucose readings, missed high- or low-glucose alerts, failed early, or failed to warn users that glucose data had stopped reporting.

This is no small complaint for someone with diabetes who relies on these monitors. A continuous glucose monitor can drive decisions about insulin, food, sleep, exercise, and emergency care. When a sensor falsely reports low glucose, a patient may eat carbohydrates or delay insulin. When a device misses a low alert, a patient may seize, lose consciousness, fall, or die. When a high glucose event is missed, the result can be prolonged hyperglycemia, diabetic ketoacidosis, hospitalization, or worse. Of course, a malfunctioning glucose monitor typically causes more minor injuries and inconveniences.

Our lawyers are looking for serious glucose monitor cases involving serious injury or death.

July 1, 2026

Social Media Addiction Lawsuit

by Ronald V. Miller, Jr.

This page is about social media addiction lawsuits and who is eligible to bring a claim. Our lawyers also provide the latest news on social media class action lawsuits (including the ongoing trial in California).

The problem that led to social media lawsuits is that millions of people, too many of whom are children, are addicted to social media platforms such as Facebook, Instagram, Snapchat, and others. For these vulnerable users, social media addiction can be very harmful and lead to things like eating disorders, depression, and, in some cases, suicide.

Now, these companies are facing a wave of new social media lawsuits alleging that they knowingly designed the algorithms of their platforms to lure young people into harmful addictions.

June 29, 2026

AFFF Firefighting Foam Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are handling AFFF firefighting foam lawsuits around the country.

This page provides the most recent news and updates on the AFFF firefighting foam class action lawsuit and our prediction of the settlement amounts that plaintiffs with AFFF cancer lawsuits can expect to receive. You will not get more updated news on the AFFF litigation anywhere else.

Our AFFF firefighting foam lawyers believe the defendants will settle most of these lawsuits this year (2026) before a single trial. Why? They will follow the same pattern as the water contamination lawsuits they settled for billions of dollars. In those cases, we saw the defendants’ apparent preference for settlement over the uncertainties of a trial. This makes sense; the AFFF lawsuits are strong cases.

June 29, 2026

Taxotere Eye Injury Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are handling Taxotere eye injury lawsuits throughout the United States for women with permanently watery eyes from docetaxel.

Taxotere (docetaxel) is a widely used breast cancer chemotherapy drug. New evidence has emerged showing that Taxotere may be causing some users to suffer permanent vision loss or damage.

This has led to a wave of product liability Taxotere lawsuits by women who claim that Taxotere damaged their eyesight. The manufacturer of Taxotere, Sanofi, allegedly knew about the risk of vision damage but chose not to warn doctors or patients about this risk.